Company dossier
Dhampur Bio Organics Limited
Current pulse
Pattern-matched earnings signal
Full receipt of the Meerganj consideration is valuable transaction proof, but continuing operations remained loss-making, EBITDA margin compressed and the profitable headline depended on discontinued operations. A post-sale debt and cash bridge is required before conviction can rise.
The asset sale delivered; recurring operations remain loss-making and margin-poor.
Continuing PBT and PAT remained losses of Rs 18.29 cr and Rs 13.75 cr, respectively.
Q1 FY2027 investor presentation, earnings call or Q2 FY2027 result
Dossier map
The asset sale delivered; recurring operations remain loss-making and margin-poor.
Revenue ₹532.89 Cr | PAT ₹36.79 Cr | EBIT margin 1.68%
This layer will track order book, execution runway, capex, capacity and pipeline as company-specific fields are populated.
Latest on-record topic: Q1 FY2027 results, segment performance and completion of the Meerganj undertaking sale
FMCG needs explicit government, rates, commodity, FX and demand sensitivity mapping.
Evidence links, management clips, filings, transcripts and source confidence are shown at the bottom of the dossier.